Full-Time

Medical Device Sales Representative

Posted on 8/21/2025

Inogen

Inogen

501-1,000 employees

Portable oxygen concentrators for home care

Compensation Overview

$64k - $73.7k/yr

+ Sales Commission Plan

Remote in USA

Remote

Category
Sales & Account Management (1)
Requirements
  • Level I: Associate degree in Sales, Technical, Business, Clinical, or related field of study, preferred.
  • Level I: Clinical background/licensure (RT, RN), preferred.
  • Level I: 2-3 years medical referral sales experience, required.
  • Level I: Basic knowledge/proficiency in Microsoft Office, required.
  • Level I: A combination of training, education and experience that is equivalent to the qualifications listed above and that provides the required knowledge, skills, and abilities.
Responsibilities
  • Procure new oxygen patient referrals to meet/exceed sales targets.
  • Represent/promote Inogen product and services to referral community.
  • Meet/exceed monthly sales call targets.
  • Deliver/set up equipment when necessary.
  • Keep detailed records of all sales activities and customer interactions.
  • Provide/execute territory sales plan, including strategic and tactical approaches that will result in successful outcomes.
  • Maintain regular and punctual attendance.
  • Comply with all company policies and procedures.
  • Assist with any other duties as assigned.
  • Create and execute territory sales plan, including strategic and tactical approaches that will result in successful outcomes.
  • Act as liaison to other departments representing Referral Development Manager's.
  • Ensure team members are adhering to standard operating procedures and retrain as necessary.
  • Make independent decisions to help guide and instruct other RDM's.
Desired Qualifications
  • Experience working with the 65+ demographic a plus.
  • Proven track record of successful team participation is required.
  • Successful experience in identifying new referral opportunities desired.

Inogen makes and sells portable oxygen concentrators for people with chronic breathing problems like COPD. These devices pull in air from the surroundings, remove nitrogen, and deliver concentrated oxygen to the user, allowing them to move around and stay independent while receiving oxygen therapy. The product is designed to be light and easy to carry, with models available to buy or rent directly from Inogen, and through a network of distributors and home medical equipment providers. What sets Inogen apart is its direct-to-consumer approach (and rental option) that bypasses traditional durable medical equipment sellers, aiming to build direct relationships with patients. The company operates in the home medical equipment market, targeting those who need long-term oxygen therapy. Its goal is to improve patients’ quality of life by providing portable, user-friendly oxygen solutions and expanding access to oxygen therapy.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Goleta, California

Founded

2001

Simplify Jobs

Simplify's Take

What believers are saying

  • Aurora CPAP masks target $2.2 billion obstructive sleep apnea market with $400 million new setup opportunity.
  • Simeox airway clearance device could add $500 million to addressable markets pending US reimbursement.
  • Yuwell Medical strategic partnership enhances global distribution and market penetration in emerging regions.

What critics are saying

  • ResMed dominates $2.2B CPAP market with 65% share, eroding Aurora margins via aggressive pricing.
  • Philips Respironics blocks Simeox US reimbursement approval, stalling revenue diversification strategy.
  • Channel shift to HME suppliers collapses direct-to-consumer rental margins, driving negative adjusted EBITDA.

What makes Inogen unique

  • 8-year expected service life on Rove 6 and One G5 outpaces competitors' 5-year standards.
  • Direct-to-consumer model builds patient relationships, bypassing traditional durable medical equipment providers.
  • Diversified respiratory platform spans oxygen, sleep therapy, airway clearance, and digital health.

Help us improve and share your feedback! Did you find this helpful?

Benefits

401(k) Retirement Plan

401(k) Company Match

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Business Wire
Mar 30th, 2026
Inogen appoints Jason Richardson as CFO and creates new CMO role to accelerate growth

Inogen, a medical technology company focused on respiratory products, has announced several leadership appointments to accelerate growth. Jason Richardson will become chief financial officer on 6 April 2026, succeeding Michael Bourque. Richardson joins from Baxter International, where he served as CFO of the Healthcare Systems & Technologies segment. Dominic Hulton has been appointed chief marketing officer, effective 1 April 2026. Hulton brings over 20 years of experience in medical technology, most recently serving as vice president of international marketing and sales excellence at Insulet Corporation. Corey Moritz joined as vice president of US business to business sales on 9 March 2026, bringing two decades of healthcare experience. The company reaffirmed its first quarter and full year 2026 financial outlook.

Yahoo Finance
Feb 26th, 2026
Inogen targets $3B market with diversified respiratory platform, launches $30M buyback

Inogen, a respiratory medical device company, reported its first full year of positive adjusted EBITDA since 2021, driven by a 4% revenue increase and cost management. The company has transformed from a single-product oxygen firm into a diversified respiratory platform covering oxygen, sleep therapy, airway clearance and digital health. The company achieved 20% unit volume growth in Q4 2025, with international revenue growing 15%. Inogen maintains a strong balance sheet with $120.9 million in cash and no debt, authorising a $30 million share repurchase programme. For 2026, Inogen projects revenue of $366 million to $373 million, with stronger growth expected in the second half following new product launches. The company targets high single-digit revenue growth and adjusted EBITDA margins of 10% or better over three to five years.

PR Newswire
Jan 27th, 2025
Arab Health 2025|Yuwell Medical Announces Strategic Investment and Partnership with Inogen in Respiratory Health

/PRNewswire/ -- On the eve of the Arab Health Exhibition, Yuwell Medical held its 2025 Global Core Partner Conference in Dubai, and announced a strategic...

Business Wire
Jan 24th, 2024
Inogen Names Michael Bourque As New Chief Financial Officer

GOLETA, Calif.--(BUSINESS WIRE)--Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Michael Bourque as Chief Financial Officer, effective March 4, 2024. Mr. Bourque has served as Treasurer and Chief Financial Officer of Chase Corporation (formally NYSE:CCF) now owned by KKR Co. Inc. He succeeds Interim Chief Financial Officer Mike Sergesketter, who will remain in an advisory role during the transition

BioSpace
Aug 7th, 2023
Inogen Achieves Best In Class 8-Year Expected Service Life Portable Oxygen Concentrators

GOLETA, Calif.--(BUSINESS WIRE)-- Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the introduction of the Rove 6™ portable oxygen concentrator in the United States with best in class 8-year expected service life.The Inogen® Rove 6™ was launched in Europe in December 2022. Having completed the necessary regulatory processes, the expected service life of the Rove 6 will be extended from 5 years to 8 years for all Rove 6 devices sold worldwide. The 8 year best-in-class expected service life has also been extended to Inogen One® G5 portable oxygen concentrators in the US.“In capital-based business models it is critical to maximize the value of the devices you invest in to enhance your returns. We are excited to now be able to extend this opportunity to Inogen’s business-to-business customers allowing them to improve the profitability of their oxygen concentrator business and strengthen the appeal of the non-delivery long-term oxygen therapy model,” said Nabil Shabshab, President and Chief Executive Officer of Inogen. “As a global market leader with a focus on delivering high quality and innovative respiratory care solutions, Inogen is well positioned to deliver the best portable oxygen concentrator for business-to-business customers, with a differentiated value proposition through a strong total cost of ownership, best-in-class quality, best after sales services, and now the best-in-class expected service life.”The Inogen® Rove 6™ is a 6-setting portable oxygen concentrator that also provides the longest battery life of any portable oxygen concentrator currently available on the market

INACTIVE